


## PHARMACEUTICAL 2023



## Matinas BioPharma Holdings Inc. Rank 146 of 446





## PHARMACEUTICAL 2023



## Matinas BioPharma Holdings Inc. Rank 146 of 446

The relative strengths and weaknesses of Matinas BioPharma Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Matinas BioPharma Holdings Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 44% points. The greatest weakness of Matinas BioPharma Holdings Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 157%, being 114% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	34,532
Cost of Goods Sold	0
Intangible Assets	4,353
Liabilities, Current	4,286
Liabilities, Non-Current	3,896
Other Assets	3,843
Other Compr. Net Income	-679
Other Expenses	0
Other Liabilities	0
Other Net Income	3,593
Other Revenues	3,188
Property and Equipment	2,091
Research and Development	16,678
Selling, General and Administrative Expense	11,100

Output Variable	Value in 1000 USD
Assets	44,819
Liabilities	8,182
Expenses	27,778
Revenues	3,188
Stockholders Equity	36,637
Net Income	-20,997
Comprehensive Net Income	-21,336
Economic Capital Ratio	157%

